GRAND RAPIDS ? BestNet has cut a deal with the Institut fur Umwelttechnologien GmbH of Berlin to demonstrate the commercial feasibility of its treatment for liver cancer.
IUT will provide development and testing services in connection with the accomplishment of the Development Feasibility Phase of its Oncosphere program. Oncosphere is the Best Net?s radioactive microsphere product for the treatment of liver cancer. This phase is the first of several development stages which, if successful, will result in FDA approval of the Oncosphere for patient treatment.
“I am confident that the demonstrated expertise of IUT combined with the knowledge of
medical device development within Oncologix will result in a successful
collaboration,? said Oncologix CEO Andrew Green. ?This agreement will position Oncologix to complete the initial development phase and prepare for the future production of testing and clinical doses.”
While this contract is only for the Development Phase for the next nine
months, discussions with IUT have resulted in an expectation that this may
be the beginning of a long term collaborative effort between the two
companies, Green said.
IUT will provide facilities, radiation handling licenses, and personnel with
experience in chemistry (inorganic, organic, and radioisotope), and proven
expertise in radiation protection, dosimetry, and radio-labeling of organic
compounds. Activities at IUT have already begun and include successful
low-activity (radiation) labeling of microspheres. If successful in the
Development phase, further collaborations would be possible for the future
phases.
IUT has established its expertise in radiation labeling of
compounds for biotechnologies, analytical analysis of radioactive
compounds, organic and inorganic chemistry, radiation and chemical
recycling, and homeland security technologies (transportation, building,
and military applications worldwide). IUT contracts with government and
industry partners worldwide to develop new technologies based on chemical
and radioactive components.
“As a further example of the global nature of our
business plans, Andrew Kennedy, our Chief Science and Medical
Officer, is meeting with leading physicians in China with Fountain
Pharmaceuticals, our licensee for Oncosphere development and sales in
China, Hong Kong and Taiwan,? Green said.
These meetings are expected to introduce the success of microsphere brachytherapy to Chinese opinion leaders and assist Fountain’s clinical introduction of the Oncosphere product in China and its development activities.”
Oncologix, based in Atlanta GA, is a wholly owned
subsidiary of BestNet Communications. Oncologix, which is in the start-up phase, develops advanced medical treatments for soft tissue cancers.
BestNet is a global solutions provider of long distance;
conference calling, ClicktoPhone and custom application-based communication
services. BestNet’s services are accessed worldwide via the Internet,
standard phones and wireless devices and are delivered using standard phone
lines and equipment.
